Pay in 4 interest-free payments of $5.94 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: A meta-analysis of randomized controlled trials
Important Disclaimers Disclaimer: Individual results may vary
Retatrutide is being studied as a triple hormone receptor agonist that targets GIP, GLP-1, and glucagon receptors
Is the patient protecting muscle as weight decreases
The age group of 3565 reported the highest number of adverse reactions, accounting for 29.62% of the total reports
US$ 20.15
US$ 23.33
US$ 28.79
